A carregar...
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized...
Na minha lista:
| Publicado no: | Antivir Chem Chemother |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6379795/ https://ncbi.nlm.nih.gov/pubmed/30776910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040206619829382 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|